Syndax Pharmaceuticals Inc. (SNDX)
Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?
The mean of analysts' price targets for Syndax (SNDX) points to a 158.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Syndax Pharmaceuticals: A Tale Of Two Drug Launches
Shares of Syndax Pharmaceuticals are still down 45% over the past three years. The Q2 report was encouraging on multiple fronts with a strong start for the Revuforj launch in KMT2A AML and Niktimvo launch in chronic GVHD. Incyte is the ideal partner for GVHD, being highly familiar with this space and the 50/50 split in the US provides a significant downside cushion to investors.
Syndax Pharmaceuticals: The Story Brightens
Syndax Pharmaceuticals just delivered strong second quarter results, beating expectations, and management also increased its long-term market opportunity projections. Both Revuforj and Niktimvo are driving rapid revenue growth, with management now targeting $10 billion in peak sales for both drugs combined. Analysts remain bullish and profitability could arrive by FY 2028, a year earlier than consensus estimates before Q2 numbers came out.
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2025 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Keith Alan Goldan - CFO, Treasurer & Chief Accounting Officer Michael A. Metzger - CEO & Director Nicholas Botwood - Head of Research and Development and Chief Medical Officer Sharon Klahre Peter Richard Lawson - Vice President of Investor Relations & Communications Steven Closter - Chief Commercial Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Dingding Shi - Jefferies LLC, Research Division Jason Eron Zemansky - BofA Securities, Research Division Justin Reid Zelin - BTIG, LLC, Research Division Kevin Strang - Goldman Sachs, Research Division Mayank Mamtani - B.
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $0.8 per share a year ago.
Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 237.8% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals
Syndax now has two approved therapies—NIKTIMVO and Revuforj—but the share price remains under pressure despite these milestones. NIKTIMVO faces a crowded cGVHD market and skepticism about its commercial potential, with analysts projecting modest long-term sales. Revuforj offers significant upside, targeting an underserved leukemia niche with minimal competition and potential for label expansion pending FDA review.
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?
The consensus price target hints at a 220% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2025 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - Chief Executive Officer and Director Steve Closter - Chief Commercial Officer Neil Gallagher - President and Head of R&D Keith Goldan - Chief Financial Officer Anjali Ganguli - Chief Strategy Officer Conference Call Participants Jason Zemansky - Bank of America Ellen Horste - TD Cowen Peter Lawson - Barclays Michael Schmidt - Guggenheim David Dai - UBS Yigal Nochomovitz - Citi Kalpit Patel - B. Riley Securities Jeet Mukherjee - BTIG Salim Syed - Mizuho George Farmer - Scotiabank Operator Good day, everyone, and welcome to the Syndax First Quarter 2025 Earnings Conference Call.
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $0.85 per share a year ago.
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2024 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q4 2024 Earnings Conference Call March 3, 2025 8:00 AM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - CEO Steve Closter - CCO Neil Gallagher - President and Head of R&D Keith Goldan - CFO Anjali Ganguli - CSO Conference Call Participants Anupam Rama - JPMorgan Brad Canino - Stifel Peter Lawson - Barclays Chris Shibutani - Goldman Sachs Kelly Shi - Jefferies Michael Schmidt - Guggenheim Yigal Nochomovitz - Citi David Dai - UBS Justin Zelin - BTIG George Farmer - Scotiabank Jason Zemansky - Bank of America Operator Good day, everyone, and welcome to the Syndax Fourth Quarter and Full Year 2024 Earnings Conference Call. Today's call is being recorded.
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.08. This compares to loss of $1 per share a year ago.
